TITLE

Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage

AUTHOR(S)
Rowe, A. Shaun; Turner, Ryan M.
PUB. DATE
March 2010
SOURCE
American Journal of Health-System Pharmacy;3/1/2010, Vol. 67 Issue 5, p361
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The use of coagulation factor VIIa (recombinant) for the treatment of warfarin-induced intracranial hemorrhage (ICH) is described. Summary. ICH is a devastating disorder that can be exacerbated by the use of oral anticoagulation. The treatment of warfarinassociated ICH involves the prompt reversal of anticoagulation to allow for surgical procedures, if necessary. Despite limited labeled indications, factor VIIa (recombinant) has been used to reverse warfarininduced anticoagulation in patients with active hemorrhage, partly due to the rapid effect of factor VIIa on the International Normalized Ratio and the ability to administer the drug quickly in acute settings. The efficacy of factor VIIa (recombinant) for the reversal of anticoagulation in patients with warfarin-associated ICH has been described in several case reports, case series, and retrospective cohort studies. Based on these reports, the use of factor VIIa (recombinant) for the treatment of warfarinassociated ICH may be a viable alternative or adjunct therapy to standard treatment with fresh-frozen plasma and vitamin K. However, due to the nature of these reports, future controlled trials should be conducted to verify the exact place for factor VIIa (recombinant) for this indication. Thromboembolic complications are rare but serious complications secondary to the use of factor VIIa (recombinant). Though differences exist in the reported rate of thromboembolic complications associated with factor VIIa (recombinant), factor VIIa (recombinant) should be used with caution in patients with a predisposition to thromboembolic complications. Conclusion. Use of factor VIIa (recombinant) may be considered for reversal of anticoagulation in patients with warfarinassociated ICH. However, patients should be screened for increased risk of thrombosis before administration of the drug.
ACCESSION #
48451018

 

Related Articles

  • HF.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1076 

    An encyclopedia entry for "HF" or "Hageman factor," which refers to the blood coagulation factor XII, is presented.

  • factor VIIa (recombinant).  // Royal Society of Medicine: Medicines;2002, p240 

    This article presents information on the blood coagulation factor VIIa. Factor VIIa is a preparation of recombinant human antihaemophilic factor VII. It acts as a drug to reduce or stop bleeding and is used to treat disorders in which bleeding is prolonged and potentially dangerous, usually...

  • Prothrombin Complex Preparations: A Cautionary Note. Ratnoff, Oscar D. // Annals of Internal Medicine;Dec74, Vol. 81 Issue 6, p852 

    Editorial. Focuses on the lethal outcome of the use of prothrombin complex preparations for treatment of bleeding. Overview of clotting factor transfusion; Consequences of prothrombin complex infusion; Recommendations.

  • Recombinant activated Factor VII not as effective as previously thought.  // Hem/Onc Today;9/10/2010, Vol. 11 Issue 17, p18 

    The article discusses research study on the influence of recombinant activated Factor VII on bleeding model parameters, published in "Blood."

  • proconvertin.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1897 

    A definition of the medical term "proconvertin," another term for coagulation factor VII, is presented.

  • Nonacog-α/prothrombin complex concentrate.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p208 

    The article presents case studies of 11 patents who developed factor IX (FIX) inhibition (FIX) during treatment with prothrombin complex concentrate and nonacog-α.

  • Effect of Depolymerized Holothurian Glycosaminoglycan (DHG) on the Activation of Factor VIII and Factor V by Thrombin. Nagase, Hideki; Enjyoji, Kei-ichi; Shima, Midori; Kitazato, Kenji; Yoshioka, Akira; Saito, Hidehiko; Kato, Hisao // Journal of Biochemistry;1996, Vol. 119 Issue 1, p63 

    Our previous study has shown that depolymerized holothurian glycosaminoglycan (DHG) has two different inhibitory activities in the blood coagulation cascade: heparin cofactor II-dependent thrombin inhibition; and antithrombin III- and heparin cofactor II-indepen-dent inhibition of the intrinsic...

  • factor VIII. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p295 

    An encyclopedia entry for "factor VIII" is presented. It refers to one of the blood proteins involved in blood clotting. A reduction in the level of factor VIII in the blood would lead to the condition called haemophilia where there is a tendency to abnormal bleeding and to prolonged bleeding...

  • Ordered adsorption of coagulation factor XII on negatively charged polymer surfaces probed by sum frequency generation vibrational spectroscopy. Xiaoyun Chen; Jie Wang; Zoltan Paszti; Fulin Wang; Schrauben, Joel N.; Tarabara, Volodymyr V.; Schmaier, Alvin H.; Zhan Chen // Analytical & Bioanalytical Chemistry;May2007, Vol. 388 Issue 1, p65 

    Electrostatic interactions between negatively charged polymer surfaces and factor XII (FXII), a blood coagulation factor, were investigated by sum frequency generation (SFG) vibrational spectroscopy, supplemented by several analytical techniques including attenuated total reflection Fourier...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics